BridgeBio Oncology Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule oncology programs for RAS and PI3Kα malignancies. Its 8-K reports cover material events such as leadership and board changes, compensatory arrangements, clinical-data press releases, and operating or financial results.
Proxy materials describe annual meeting matters, director elections, board classification, auditor ratification, and governance practices. The company’s filings also identify its common stock capital structure and formal disclosure categories for clinical and regulatory updates, governance, compensation, and public-company reporting obligations.
BridgeBio Oncology Therapeutics (BBOT) filed its Q3 2025 10‑Q, highlighting a post‑de‑SPAC balance sheet and higher operating spend as programs scale. Cash and cash equivalents were $408.7 million and short‑term marketable securities were $59.5 million, for total liquidity of $468.3 million as of September 30, 2025. The company reported a net loss of $44.8 million for the quarter as operating expenses reached $49.2 million (R&D $35.1 million; G&A $14.1 million), with interest income of $3.4 million and $1.0 million from a transition services agreement.
BBOT completed its de‑SPAC on August 11, 2025, including a $260.9 million PIPE and $120.9 million from the SPAC trust, and ended the quarter with 79,196,710 shares outstanding. For the nine months, net loss was $95.2 million as the company advanced RAS and PI3K oncology programs and established public‑company infrastructure. Management states existing cash, cash equivalents, and marketable securities are expected to support operations for at least one year from issuance.
BridgeBio Oncology Therapeutics (BBOT) furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The company states the press release is provided under Item 2.02 and is being furnished, not filed, meaning it is not subject to Section 18 liabilities of the Exchange Act. The filing includes Exhibit 99.1 (the press release dated November 12, 2025) and Exhibit 104 (the cover page Inline XBRL data).
BridgeBio Oncology Therapeutics, Inc. filed a Form S-8 to register securities under several employee benefit plans following corporate changes that include a domestication to Delaware and a name change. The filing discloses that TheRas, Inc. merged into a Merger Sub, leaving TheRas as a direct, wholly owned subsidiary, and that an Inducement Plan was adopted by the board under Nasdaq Rule 5635(c)(4) without stockholder approval. The registration references prior filings including the Form 10-K for year ended December 31, 2024 and subsequent 10-Qs, and incorporates the company’s Certificate of Incorporation and Bylaws by reference. Exhibits listed include the 2025 equity plans, the 2016 TheRas plan, legal opinions, auditor consents, and a filing-fee table. Signature blocks show directors and dates of October 10, 2025.
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported a Form 4 disclosing that Eli M. Wallace, who serves as Chief Executive Officer and a director, was granted a stock option on 10/02/2025. The option covers 1,614,400 shares of common stock with an exercise price of $12.44 per share and an expiration date of 10/01/2035. The option becomes exercisable in equal monthly installments equal to 1/48th of the total award, beginning on 10/02/2025, subject to continued service. The reporting person is shown as the direct holder of the option and the Form 4 was signed by an attorney-in-fact on 10/06/2025.